Abstract
Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Current Cancer Therapy Reviews
Title:Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Volume: 12 Issue: 1
Author(s): Diego Touya, Kathrin Strasser-Weippl, Ann Whalen, Jessica St. Louis and Paul Goss
Affiliation:
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Abstract: Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Export Options
About this article
Cite this article as:
Touya Diego, Strasser-Weippl Kathrin, Whalen Ann, Louis St. Jessica and Goss Paul, Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160617081058
DOI https://dx.doi.org/10.2174/1573394712666160617081058 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radioactive Gold Nanoparticle in Two Forms (<sup>198</sup><sub>79</sub>Au GNPs and <sup>99m</sup>Tc-GNPs) for Lung Cancer Antiproliferative Induction and Intralesional Imaging: A Proof of Concept
Anti-Cancer Agents in Medicinal Chemistry Pd/C-catalyzed Synthesis of (E)-2-arylmethylideneindolin-3-ols Under Ultrasound: Their Initial Evaluation as Potential Anti-proliferative Agents
Letters in Drug Design & Discovery Microtubules in Apoptosis Induction: Are They Necessary?
Current Cancer Drug Targets Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Tracing the Origins of COX-2 Inhibitors Structures+
Current Medicinal Chemistry Recent Advances in Metabolomics
Current Metabolomics HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Current Treatment for Cervical Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design An Image-Based Biosensor Assay Strategy to Screen for Modulators of the microRNA 21 Biogenesis Pathway
Combinatorial Chemistry & High Throughput Screening Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Smart Triggered Release in Controlled Drug Delivery
Current Drug Targets Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry